Business Context and Reporting Period
Company: ChromaDex Corp. (Note: Input metadata referenced "Niagen Bioscience, Inc.", but the filing identifies the registrant as ChromaDex Corp.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2013
Event: Entry into a Material Definitive Agreement with Thorne Research, Inc. for the supply and marketing of the patented product Niagen (nicotinamide riboside).
Key Financial Metrics and Agreement Terms
This filing details a three-year supply agreement rather than a standard financial performance report. Key financial terms include:
- Upfront Payment: Thorne Research agreed to pre-pay $168,000 upon execution of the agreement.
- Year 1 Minimum Purchase Obligation: $500,000 total, structured in three installments:
- Order 1: $168,000 (140 kg @ $1,200/kg), payable August 1, 2013.
- Order 2: $168,000 (140 kg @ $1,200/kg), payable December 23, 2013.
- Order 3: $165,000 (150 kg @ $1,100/kg), payable April 21, 2014.
- Subsequent Year Milestones: Exclusivity in Year 2 requires $1,000,000 in purchases; Year 3 requires $2,000,000.
- Royalties: Thorne will pay a 5% royalty on combined net sales of the Product.
- Additional Funding: Thorne agreed to fund and collaborate on current and future clinical studies (specific amounts not disclosed).
Liquidity and Debt: The filing text does not provide clear values for the company's overall cash flow, debt levels, or liquidity position outside of the specific transaction terms.
Material Changes and Strategic Shifts
The primary material change is the establishment of an exclusive distribution channel for Niagen in the United States and Canada for the direct-to-healthcare-practitioner market. This agreement secures a defined revenue stream for the first year and sets aggressive growth targets for subsequent years to maintain exclusivity.
Outlook, Risks, and Contingencies
- Exclusivity Contingency: The exclusive rights granted to Thorne are conditional. If Thorne fails to meet the $1,000,000 (Year 2) or $2,000,000 (Year 3) purchase minimums, the exclusivity provisions will cease to be effective.
- Forward-Looking Statements: The filing includes standard disclaimers that projections regarding intent, beliefs, and expectations are subject to risks and uncertainties that could cause actual results to differ significantly.
- Clinical Collaboration: Future revenue and product validation depend on the success of clinical studies funded by Thorne.
Investor Verification Checklist
- Verify the receipt of the $168,000 pre-payment and subsequent installment payments as scheduled.
- Monitor Thorne Research's ability to meet the Year 2 ($1M) and Year 3 ($2M) purchase milestones to maintain exclusivity.
- Review the specific terms of the clinical study funding and collaboration to assess potential R&D cost offsets.
- Confirm the definition of "combined net sales" in the full agreement (Exhibit 99.1) to understand royalty calculation mechanics.